RBM23 Drives Hepatocellular Carcinoma by Activating NF-κB Signaling Pathway.
Hexu HanTing LinZiyi FangGuoxiong ZhouPublished in: BioMed research international (2021)
Firstly, we analyzed the correlation of clinical specimens. In HCC tissues, the levels of RBM23 and microvessel density (MVD) showed a strong positive correlation. Furthermore, data from related cytology experiments showed that the knockdown of RBM23 expression in HCC cells significantly inhibited the tube formation by the human vascular endothelial cells in vitro. The mechanism of this phenomenon was found to be through increasing the mRNA of p65 and enhanced the nuclear accumulation of p65. Consequently, RBM23 activated the NF-κB signaling pathway and promoted expression of the proangiogenic cytokines selectively. Results and Conclusion. In summary, this study revealed that RBM23 promotes the angiogenesis properties of HCC via the NF-κB signaling pathway. It may, therefore, be a potential therapeutic target for the treatment of hepatocellular carcinoma.
Keyphrases
- signaling pathway
- induced apoptosis
- endothelial cells
- pi k akt
- cell cycle arrest
- poor prognosis
- epithelial mesenchymal transition
- binding protein
- fine needle aspiration
- high glucose
- oxidative stress
- lps induced
- long non coding rna
- single cell
- machine learning
- electronic health record
- immune response
- endoplasmic reticulum stress
- big data
- induced pluripotent stem cells
- nuclear factor
- risk assessment
- cell death
- deep learning
- human health
- toll like receptor